Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's flagship candidate, ACOG-100, seeks to improve cognitive function and tackle significant unmet needs among the aging demographic. With a robust proprietary neuroscience platform and a deep commitment to rigorous research and development, Alpha Cognition is well-positioned for growth as it advances its clinical pipeline and explores new therapeutic avenues. For institutional investors, the company presents a compelling opportunity to contribute to transformative patient care while capitalizing on the expanding healthcare sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$9.52
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 13, 2026 | $-0.39 | $-0.40 | Miss -2.6% | $-0.40 | — | $6.1M | — | 1D Pre+0.7% | On-Day-3.6% | 1D Post+2.4% |
Q ended Mar 31, 2026 Reported May 14, 2026 | $-0.39 | $-0.32 | Beat +17.9% | $-0.32 | — | $3.5M | — | 1D Pre+8.4% | On-Day-4.5% | 1D Post+6.0% |
Q ended Dec 31, 2025 Reported Mar 26, 2026 | $-0.35 | $-0.31 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Beat +11.4% |
| — |
| — |
| $2.8M |
| — |
| 1D Pre-4.8% |
| On-Day+0.4% |
| 1D Post-4.9% |
Q ended Sep 30, 2025 Reported Nov 13, 2025 | $-0.43 | $-0.30 | Beat +30.2% | — | — | $2.8M | — | 1D Pre0.0% | On-Day+0.2% | 1D Post-3.1% |